MC4R's appetite-reducing effect, secondary to the promotion of satiety and energy use, makes it an ideal therapeutic target; setmelanotide is especially beneficial for individuals with obesity related to POMC or MSH deficiency. The gene discussed is POMC; the disease is obesity disorder.